PRLD
Prelude Therapeutics Incorporated
There isn't enough reported data to score PRLD yet.
PRLD Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Under pressure | |
| Unavailable |
PRLD's profitability and cash flow are currently under pressure. There isn't enough data to rate its revenue and balance sheet.
PRLD PE Valuation
PRLD has no meaningful PE right now: it lost money over the past year.
PRLD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Moderate |
Analysts expect PRLD's losses to grow, with revenue declining.
PRLD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.73 | +$0.90 |
| Q1 2026 | -$1.00 | +$0.68 |
| Q4 2025 | -$1.29 | +$0.39 |
| Q3 2025 | -$1.46 | +$0.30 |
| Q2 2025 | -$1.63 | +$0.15 |
| Q1 2025 | -$1.68 | +$0.18 |
| Q4 2024 | -$1.68 | +$0.34 |
| Q3 2024 | -$1.76 | +$0.41 |
PRLD is still losing money, but far less than before: $0.73 per share over the past year, against $2.59 at its worst in early 2022.
PRLD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $5.6M | +41% |
| Q3 2025 | $6.5M | +117% |
PRLD's revenue has grown year over year every quarter since late 2024: $6M last quarter, up 43% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -271% | N/A |
| Q1 2026 | -310% | N/A |
| Q4 2025 | -308% | +538 points |
| Q3 2025 | -314% | +832 points |
| Q4 2024 | -846% | N/A |
| Q3 2024 | -1146% | N/A |
PRLD's operating margin was −271% last quarter, up 575 points from the same quarter a year ago.
PRLD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$15.6M | +$10.5M |
| Q1 2026 | -$21.7M | +$12.6M |
| Q4 2025 | $23.1M | +$43.9M |
| Q3 2025 | -$19.1M | +$8.2M |
| Q2 2025 | -$26.1M | -$2.7M |
| Q1 2025 | -$34.3M | -$2.2M |
| Q4 2024 | -$20.8M | +$3.9M |
| Q3 2024 | -$27.4M | -$1.1M |
PRLD has burned cash in almost every quarter: −$33M over the past year, against −$109M the year before.
PRLD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +19% | +15.9M shares |
| 1 year | +29% | +22.4M shares |
| 3 years | +106% | +50.7M shares |
| 5 years | +118% | +53.3M shares |
PRLD has 98M diluted shares, up 29% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
| Q3 2019 | — |
PRLD Net Leverage
PRLD's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
PRLD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.7 | Neutral |
| Stochastic | 13.3 | Oversold |
PRLD's weekly RSI is 45 (neutral) and its Stochastic is 13 (oversold).
PRLD PE vs Healthcare Sector
PRLD has no meaningful PE right now: it lost money over the past year.
PRLD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.67 | 4.1% below |
| 20 week MA | $4.46 | 21% below |
| 50 week MA | $3.73 | 5.6% below |
| 100 week MA | $2.39 | 47% above |
| 200 week MA | $3.26 | 8% above |
PRLD has slipped below its 8-, 20- and 50-week averages, though it's still 8% above its 200-week average.
PRLD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $26.2 | $88.9 | +239% |
| 2021 | $88.9 | $13.7 | -85% |
| 2022 | $13.7 | $5.10 | -63% |
| 2023 | $5.10 | $4.27 | -16% |
| 2024 | $4.27 | $1.34 | -69% |
| 2025 | $1.34 | $2.45 | +83% |
| 2026 YTD | $2.45 | $3.52 | +44% |
PRLD's yearly returns have swung widely, from +239% in 2020 to −85% in 2021. It's up 44% so far in 2026.